Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis

Front Immunol. 2023 May 22:14:1186357. doi: 10.3389/fimmu.2023.1186357. eCollection 2023.

Abstract

Background: While recent studies have separately explored mutational signatures and the tumor microenvironment (TME), there is limited research on the associations of both factors in a pan-cancer context.

Materials and methods: We performed a pan-cancer analysis of over 8,000 tumor samples from The Cancer Genome Atlas (TCGA) project. Machine learning methods were employed to systematically explore the relationship between mutational signatures and TME and develop a risk score based on TME-associated mutational signatures to predict patient survival outcomes. We also constructed an interaction model to explore how mutational signatures and TME interact and influence cancer prognosis.

Results: Our analysis revealed a varied association between mutational signatures and TME, with the Clock-like signature showing the most widespread influence. Risk scores based on mutational signatures mainly induced by Clock-like and AID/APOBEC activity exhibited strong pan-cancer survival stratification ability. We also propose a novel approach to predict transcriptome decomposed infiltration levels using genome-derived mutational signatures as an alternative approach for exploring TME cell types when transcriptome data are unavailable. Our comprehensive analysis revealed that certain mutational signatures and their interaction with immune cells significantly impact clinical outcomes in particular cancer types. For instance, T cell infiltration levels only served as a prognostic biomarker in melanoma patients with high ultraviolet radiation exposure, breast cancer patients with high homologous recombination deficiency signature, and lung adenocarcinoma patients with high tobacco-associated mutational signature.

Conclusion: Our study comprehensively explains the complex interplay between mutational signatures and immune infiltration in cancer. The results highlight the importance of considering both mutational signatures and immune phenotypes in cancer research and their significant implications for developing personalized cancer treatments and more effective immunotherapy.

Keywords: cancer genomics; cancer prognosis; immunotherapy; mutational signatures; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung*
  • Humans
  • Lung Neoplasms* / genetics
  • Melanoma*
  • Mutation
  • Tumor Microenvironment / genetics
  • Ultraviolet Rays

Grants and funding

This work was supported by National key R&D Program of China (2021YFA1302100 to QZ), Guangdong Basic and Applied Basic Research Foundation (2021A1515011743 to QZ), China Postdoctoral Science Foundation (2021M703733 to SW), Youth Talent Support Program of Guangdong Provincial Association for Science and Technology (SKXRC202313 to QZ).